Nanosilver Non-Toxic in New Human Clinical Study
In a brand new clinical study titled “In vivo Human Time-exposure Study of Orally Dosed Commercial Silver Nanoparticles,” published in October 2014 in the journal Nanomedicine, clinical researchers from the University of Utah demonstrated the lack of toxicity to humans of orally-ingested nanoscale colloidal silver at both 10 ppm and 32 ppm concentrations.
According to the study authors, “We prospectively studied commercial 10- and 32-ppm nanoscale silver particle solutions in a single-blind, controlled, cross-over, intent-to-treat, design. Healthy subjects (n = 60) underwent metabolic, blood counts, urinalysis, sputum induction, and chest and abdomen magnetic resonance imaging. Silver serum and urine content were determined. No clinically important changes in metabolic, hematologic, or urinalysis measures were identified. No morphological changes were detected in the lungs, heart or abdominal organs. No significant changes were noted in pulmonary reactive oxygen species or pro-inflammatory cytokine generation. In vivo oral exposure to these commercial nanoscale silver particle solutions does not prompt clinically important changes in human metabolic, hematologic, urine, physical findings or imaging morphology. Further study of increasing time exposure and dosing of silver nanoparticulate silver, and observation of additional organ systems are warranted to assert human toxicity thresholds.” In short, no toxicity whatsoever to the human body was demonstrated during the 14-day trial.
The researchers concluded, “We have demonstrated that 14- day monitored human oral dosing of a commercial oral nanoparticle silver colloidal product does not produce observable clinically important toxicity markers. Further study of nanomaterials over longer human exposures is clearly warranted…”
